The Journal of Clinical Pharmacology最新文献

筛选
英文 中文
Ketamine Dose and Duration Effects in Internalizing Disorders 氯胺酮剂量和持续时间对内化障碍的影响。
The Journal of Clinical Pharmacology Pub Date : 2026-09-16 DOI: 10.1002/jcph.70299
Neil McNaughton PhD, Ben Beaglehole FRANZCP, Paul Glue FRCPsych
{"title":"Ketamine Dose and Duration Effects in Internalizing Disorders","authors":"Neil McNaughton PhD,&nbsp;Ben Beaglehole FRANZCP,&nbsp;Paul Glue FRCPsych","doi":"10.1002/jcph.70299","DOIUrl":"10.1002/jcph.70299","url":null,"abstract":"<p>The dose-response profile of racemic ketamine in internalizing disorders is poorly characterized. This was a secondary analysis of outcome responses in patients with treatment-resistant depression, post-traumatic stress disorder, generalized and/or social anxiety, or obsessive-compulsive disorder. For each disorder, they received single intramuscular doses of racemic ketamine (0.5 and 1.0 mg/kg) and a psychoactive control, using a three-way within-subject double-blind active-controlled cross-over design. Intramuscular racemic ketamine doses of 0.5 and 1.0 mg/kg produced robust effects on diagnosis-appropriate outcome scales for all these internalizing disorders, compared with psychoactive controls. These effects were most obvious at 24 h after dosing and noticeably smaller at 168 h. The magnitude of change after 1 mg/kg did not differ significantly from 0.5 mg/kg at either time point, and did not differ significantly between the internalizing disorders at 24 h. When combined with other ketamine dose-response data, we propose that ketamine may have a narrow inverted-U dose-response profile (peaking in the regions of 0.5-1.0 mg/kg) in patients with internalizing disorders.</p>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13579490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148978365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endogenous Biomarkers to Evaluate Transporter-Mediated Drug–Drug Interactions: Current Evidence, Impact on Clinical Pharmacology Strategy, Remaining Gaps, and Future Directions 内源性生物标志物评估转运体介导的药物-药物相互作用:目前的证据,对临床药理学策略的影响,剩余的差距和未来的方向。
The Journal of Clinical Pharmacology Pub Date : 2026-09-16 DOI: 10.1002/jcph.70280
Laura E. Russell PhD, Fenglei Huang PhD,FCP, Kit Wun Kathy Cheung PharmD, Manthena V. S. Varma PhD, Vijender Panduga PhD
{"title":"Endogenous Biomarkers to Evaluate Transporter-Mediated Drug–Drug Interactions: Current Evidence, Impact on Clinical Pharmacology Strategy, Remaining Gaps, and Future Directions","authors":"Laura E. Russell PhD,&nbsp;Fenglei Huang PhD,FCP,&nbsp;Kit Wun Kathy Cheung PharmD,&nbsp;Manthena V. S. Varma PhD,&nbsp;Vijender Panduga PhD","doi":"10.1002/jcph.70280","DOIUrl":"10.1002/jcph.70280","url":null,"abstract":"<p>Endogenous biomarkers have gained considerable attention as tools for assessing transporter-mediated drug–drug interactions (tDDIs). While plasma coproporphyrin I is considered a validated biomarker for assessing hepatic organic anion transporting polypeptide (OATP) 1B-mediated DDI risk, data supporting biomarkers for other major drug transporters, particularly renal transporters, remains limited. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) included endogenous biomarker-based assessments in its recent guidance, ICH M12, as an alternative approach for evaluating tDDIs, which is anticipated to broaden the use of this strategy in early clinical development. However, methodological gaps remain in biomarker measurement, including study design, biological matrix selection, and data analysis. Importantly, consensus is still needed on the most appropriate biomarkers for renal organic cation transporter (OCT) 2 and multidrug and toxin extrusion (MATE) transporters 1 and 2-K, such as creatinine, N<sup>1</sup>-methylnicotinamide, and N<sup>1</sup>-methyladenosine, given the influence of various extrinsic and intrinsic factors on their performance. This review aims to summarize the current state of clinical evidence for endogenous biomarkers of major hepatic and renal transporters, including study design considerations relevant to meaningful data interpretation. It also briefly summarizes reported Physiologically based pharmacokinetic (PBPK) models of these biomarkers, highlights key gaps in current understanding, and identifies future work needed to expand the application of a biomarker-based tDDI strategy.</p>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148978376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quantitative Systems Pharmacology (QSP): Bridging Biology and Mechanism with Clinical Drug Development Decisions 定量系统药理学(QSP):连接生物学和机制与临床药物开发决策。
The Journal of Clinical Pharmacology Pub Date : 2026-09-15 DOI: 10.1002/jcph.70289
Weirong Wang PhD, Alexander V. Ratushny PhD, Steve Chang MS, Yougan Cheng PhD, Jingqi Q. X. Gong PhD, Abhishek Gulati PhD, Emma Hansson PhD, Alexander Kulesza PhD, Federico Reali PhD, Conner Sandefur PhD, Brian J. Schmidt PhD, Fulya Akpinar Singh PhD, Monica E. Susilo PhD, Susana Zaph PhD, Blerta Shtylla PhD
{"title":"Quantitative Systems Pharmacology (QSP): Bridging Biology and Mechanism with Clinical Drug Development Decisions","authors":"Weirong Wang PhD,&nbsp;Alexander V. Ratushny PhD,&nbsp;Steve Chang MS,&nbsp;Yougan Cheng PhD,&nbsp;Jingqi Q. X. Gong PhD,&nbsp;Abhishek Gulati PhD,&nbsp;Emma Hansson PhD,&nbsp;Alexander Kulesza PhD,&nbsp;Federico Reali PhD,&nbsp;Conner Sandefur PhD,&nbsp;Brian J. Schmidt PhD,&nbsp;Fulya Akpinar Singh PhD,&nbsp;Monica E. Susilo PhD,&nbsp;Susana Zaph PhD,&nbsp;Blerta Shtylla PhD","doi":"10.1002/jcph.70289","DOIUrl":"10.1002/jcph.70289","url":null,"abstract":"<div>\u0000 \u0000 <p>Quantitative systems pharmacology (QSP) integrates mechanistic representations of biology with quantitative pharmacology to support decision‑making across the drug development continuum. Over the past two decades, QSP has evolved from an exploratory research activity into an established component of model‑informed drug development (MIDD), particularly in settings where system‑level interactions complicate the interpretation of exposure–response relationships or where direct clinical data are limited. This review outlines the historical development and conceptual foundations of QSP and summarizes representative clinical applications spanning early, mid, and late development. Examples highlight how QSP is used to support mechanism-based dose and regimen selection, optimization of combination strategies, biomarker‑informed patient stratification, and lifecycle management decisions. We also discuss considerations for rigor, credibility, and trustworthiness in alignment with the ICH M15 framework, emphasizing clearly defined questions of interest, context of use, and proportional, decision-driven evaluation of assumptions and uncertainty. Finally, we consider emerging challenges and opportunities for QSP adoption, including reuse of platform models, integration of multi-omics data, and selective incorporation of AI-enabled methods within mechanistically interpretable frameworks.</p>\u0000 </div>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148971817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Population Pharmacokinetics and Exposure–Response of Sasanlimab, a Checkpoint Inhibitor, in Patients with Non-Muscle Invasive Bladder Cancer and Other Solid Tumors 非肌肉侵袭性膀胱癌和其他实体肿瘤患者中检查点抑制剂沙三力单的人群药代动力学和暴露反应
The Journal of Clinical Pharmacology Pub Date : 2026-09-15 DOI: 10.1002/jcph.70295
Joanna C. Masters PharmD, FCP, Brian Jermain PharmD, Alan Liu PhD, Rossano Cesari PharmD, PhD, Anna Maria Calella PhD, Elisabete Michelon MD, Caimiao Wei PhD, Susana Liu MSCi, Joseph Piscitelli PharmD
{"title":"Population Pharmacokinetics and Exposure–Response of Sasanlimab, a Checkpoint Inhibitor, in Patients with Non-Muscle Invasive Bladder Cancer and Other Solid Tumors","authors":"Joanna C. Masters PharmD, FCP,&nbsp;Brian Jermain PharmD,&nbsp;Alan Liu PhD,&nbsp;Rossano Cesari PharmD, PhD,&nbsp;Anna Maria Calella PhD,&nbsp;Elisabete Michelon MD,&nbsp;Caimiao Wei PhD,&nbsp;Susana Liu MSCi,&nbsp;Joseph Piscitelli PharmD","doi":"10.1002/jcph.70295","DOIUrl":"10.1002/jcph.70295","url":null,"abstract":"<p>Sasanlimab is a monoclonal antibody (mAb) which blocks human programed cell death protein 1. It is administered subcutaneously (SC), currently under development for non-muscle invasive bladder cancer (NMIBC) with a recommended flat dose of 300 mg every 4 weeks (Q4W). The objectives of the analyses were to characterize the population pharmacokinetics (popPK) of sasanlimab and to determine the exposure–response (ER) relationship between sasanlimab and safety endpoints of interest pooling data across clinical studies including various tumor types. Analyses for efficacy aimed to determine additional ER relationships within the NMIBC population. Sasanlimab PK was typical of IgG4 mAbs and was well characterized by a two-compartment model, with a small volume of distribution (central volume of 3.67 L, peripheral volume of 2.19 L), low systemic clearance (0.142 L/day), and elimination half-life of ∼29 days. Bioavailability from SC dosing was ∼70%. There was no evidence of time-dependent change in sasanlimab clearance, and no meaningful impact of body weight on exposure. There was no association found between sasanlimab exposure and any safety endpoint of interest: treatment-emergent adverse events of Grade ≥2 and Grade ≥3, and immune-related adverse events of Any Grade and Grade ≥3. For efficacy, no association was found between exposure and the key endpoints: investigator-assessed event free survival and complete response (in participants with carcinoma in situ). In total, the popPK results and absence of ER associations for safety and efficacy endpoints support the recommended flat dose of sasanlimab 300 mg SC Q4W.</p>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13576834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148971859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nipocalimab Phase 3 Dose Selection for Severe Hemolytic Disease of the Fetus and Newborn 尼波卡利单抗用于胎儿和新生儿严重溶血性疾病的3期剂量选择
The Journal of Clinical Pharmacology Pub Date : 2026-09-11 DOI: 10.1002/jcph.70259
Jie Zhou PhD, Yuan Xiong PhD, Edwin Lam PharmD, Leona E. Ling PhD, Shumyla Saeed-Khawaja MD, Yosuke Komatsu MD, PhD, An Vermeulen PhD, Mahesh N. Samtani PhD, Jocelyn H. Leu PharmD, PhD
{"title":"Nipocalimab Phase 3 Dose Selection for Severe Hemolytic Disease of the Fetus and Newborn","authors":"Jie Zhou PhD,&nbsp;Yuan Xiong PhD,&nbsp;Edwin Lam PharmD,&nbsp;Leona E. Ling PhD,&nbsp;Shumyla Saeed-Khawaja MD,&nbsp;Yosuke Komatsu MD, PhD,&nbsp;An Vermeulen PhD,&nbsp;Mahesh N. Samtani PhD,&nbsp;Jocelyn H. Leu PharmD, PhD","doi":"10.1002/jcph.70259","DOIUrl":"https://doi.org/10.1002/jcph.70259","url":null,"abstract":"<p>Nipocalimab, a neonatal Fc receptor (FcRn) blocker, is under evaluation for severe hemolytic disease of the fetus and newborn (HDFN). In the Phase 2 UNITY trial, weekly intravenous antenatal treatment with nipocalimab at dose regimens of 30 and 45 mg/kg prevented fetal anemia requiring intrauterine transfusion (IUT) in 54% of high-risk pregnancies and delayed the need for IUTs versus their previous pregnancies in the remaining 46% of pregnancies. This analysis aimed to select a weekly dose regimen of nipocalimab for the Phase 3 study in severe HDFN (NCT05912517) that maintains FcRn blockade throughout antenatal treatment, including with an unplanned dosing delay of up to 3 days. Observed pharmacokinetic/pharmacodynamic (PK/PD) data from UNITY (i.e., nipocalimab concentrations, FcRn occupancy, and serum IgG) were analyzed using a model-based approach. A PK/PD model originally developed in nonpregnant participants was updated to incorporate gestational weight gain. Nipocalimab PK and FcRn occupancy were described by a two-compartment model with nonlinear, dose-dependent PK, which captured longitudinal PK, FcRn occupancy, and IgG profiles during dosing and return toward baseline postpartum after discontinuation. Both 30 and 45 mg/kg achieved ∼80%–85% reductions in maternal IgG; however, 30 mg/kg showed greater variability in predose trough concentrations, increasing the risk of falling below concentrations required for full FcRn occupancy across antenatal treatment. Simulations incorporating PK/PD variability indicated that 45 mg/kg weekly per current weight maintained full FcRn occupancy in &gt;95% of pregnant individuals, even with dosing delays up to 3 days. Exploratory exposure–response analyses supported 45 mg/kg for the Phase 3 HDFN study.</p>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcph.70259","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148943272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacokinetics and Pharmacodynamics of Antimalarial Agents: Optimizing Combination Therapies to Overcome Resistance Mechanisms 抗疟药物的药代动力学和药效学:优化联合治疗以克服耐药机制。
The Journal of Clinical Pharmacology Pub Date : 2026-09-10 DOI: 10.1002/jcph.70291
Kiana Pica MS, Oliver Grundmann MS, PhD, FCP, Francine Johansson Azeredo BPharm, PhD
{"title":"Pharmacokinetics and Pharmacodynamics of Antimalarial Agents: Optimizing Combination Therapies to Overcome Resistance Mechanisms","authors":"Kiana Pica MS,&nbsp;Oliver Grundmann MS, PhD, FCP,&nbsp;Francine Johansson Azeredo BPharm, PhD","doi":"10.1002/jcph.70291","DOIUrl":"10.1002/jcph.70291","url":null,"abstract":"<p>Malaria remains a persistent global health challenge, worsened by the emergence of drug-resistant <i>Plasmodium</i> strains. This review synthesizes the pharmacokinetics (PK) and pharmacodynamics (PD) of key antimalarial agents, evaluating how these properties influence the performance of current pharmacological regimens. Findings in the literature indicate that artemisinin-based combination therapies (ACTs) achieve rapid parasite clearance by using short-acting artemisinin derivatives paired with longer-acting partner drugs. PK/PD modeling consistently demonstrates that well-matched half-lives and sustained post-treatment exposure are critical to prevent functional monotherapy-related resistance. Non-artemisinin and triple combination regimens show promise in overcoming multidrug resistance, but gaps remain in exposure–response characterization, dose alignment, and population-specific optimization. A discussion of PK/PD modeling across agents, including chloroquine, artemisinin and its derivatives, mefloquine, primaquine, and tafenoquine, highlights how inadequate drug exposure, mismatched partner drug kinetics, and host metabolic variability contribute to treatment failure. Collectively, the evidence suggests that refining combination regimens through PK/PD-guided dose optimization is crucial for maintaining efficacy and preventing resistance. Future research must prioritize host-specific factors, stage-specific drug activity, and optimized combination regimens to improve therapeutic outcomes and support malaria eradication.</p>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148921462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Rise of the Digital Health Technology–AI Coupled System in the AI Era of Drug Development 药物研发人工智能时代,数字健康技术-人工智能耦合系统的兴起
The Journal of Clinical Pharmacology Pub Date : 2026-09-09 DOI: 10.1002/jcph.70287
Hanrui Zhang PhD, Gabriel K. Innes PhD, Jonas Santiago MS,PharmD, Ayoub Suliman PharmD, Norah Xiao MS, Hao Zhu PhD, Dianne Paraoan MS, Jeffery Siegel MD, Yutao Gong PhD, Ruihao Huang PhD, Menglun Wang PhD, Lixia Zhang PhD, Qi Liu PhD
{"title":"The Rise of the Digital Health Technology–AI Coupled System in the AI Era of Drug Development","authors":"Hanrui Zhang PhD,&nbsp;Gabriel K. Innes PhD,&nbsp;Jonas Santiago MS,PharmD,&nbsp;Ayoub Suliman PharmD,&nbsp;Norah Xiao MS,&nbsp;Hao Zhu PhD,&nbsp;Dianne Paraoan MS,&nbsp;Jeffery Siegel MD,&nbsp;Yutao Gong PhD,&nbsp;Ruihao Huang PhD,&nbsp;Menglun Wang PhD,&nbsp;Lixia Zhang PhD,&nbsp;Qi Liu PhD","doi":"10.1002/jcph.70287","DOIUrl":"10.1002/jcph.70287","url":null,"abstract":"&lt;p&gt;The modern clinical investigation is undergoing a profound structural evolution. Previously, a comprehensive landscape analysis of regulatory submissions to the US Food and Drug Administration (FDA) during 2016 to 2021 demonstrated a rapid, exponential increase in the application of artificial intelligence and machine learning (AI/ML) across the drug development lifecycle.&lt;span&gt;&lt;sup&gt;1, 2&lt;/sup&gt;&lt;/span&gt; At the same time, an expansion of digital health technologies (DHTs) in drug development is also observed, such as smart watches, phone applications, and other mobile technologies, enabling continuous capture of vital physiological and behavioral data real-time and remotely outside of traditional trial site.&lt;span&gt;&lt;sup&gt;3-5&lt;/sup&gt;&lt;/span&gt; However, these technologies are not advancing in isolation; many DHT applications have the potential to be intrinsically coupled with AI.&lt;/p&gt;&lt;p&gt;For the purposes of this commentary, we explore these coupled technologies as an AI–DHT coupled system. The AI–DHT coupled system describes the synergistic relationship between DHTs and AI in drug development. Within this emerging AI–DHT coupled system, DHT collects large amounts of data from patients remotely outside of traditional clinical trial sites, and AI can provide the necessary computational engine for signal processing, feature selection, and clinical translation. Together, they are driving a steady paradigm shift in drug development, gradually augmenting the traditional, episodic, site-centric model with a continuous, patient-centric model, as reflected in FDA's guidance on conducting clinical trials with decentralized element&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; (Figure 1).&lt;/p&gt;&lt;p&gt;To fully appreciate the scope of this evolving relationship, it is essential to trace how the AI–DHT coupled system is embedded into the operational and clinical continuum of drug development. Rather than serving as isolated point solutions, these coupled technologies create a continuous thread of data generation and algorithmic translation in all stages of clinical trials. In reviewing recent regulatory submissions, the use of this AI–DHT coupled system can be mapped across four distinct chronological phases: optimizing initial trial enrollment, engagement, and protocol adherence; establishing baseline digital phenotypes for trial enrichment; conducting active safety surveillance; and developing novel digitally derived endpoints and biomarkers.&lt;/p&gt;&lt;p&gt;The initial impact of the AI–DHT coupled system is observed directly in promoting trial enrollment and expanding patient access to clinical trials. AI–DHT coupled systems can help patient enrollment in trials through automation of enrollment procedures or enabling timely enrollment of patients with acute and transient conditions, for example, patients with sepsis in emergency department, where the onset could take from a few hours to a few days. By leveraging the remote data collection capabilities established by DHTs, investigators can also enroll hist","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcph.70287","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148913482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Model-Informed Dose Selection of Intranasal Epinephrine in Young Children 基于模型的儿童鼻内肾上腺素剂量选择。
The Journal of Clinical Pharmacology Pub Date : 2026-09-09 DOI: 10.1002/jcph.70294
Manav Jain MD, Priscila A Yamamoto PhD, Amira Soliman PhD, Richard Lowenthal MSc, Valvanera Vozmediano PhD, Stephan Schmidt PhD, FCP, Natalia de Moraes PhD
{"title":"Model-Informed Dose Selection of Intranasal Epinephrine in Young Children","authors":"Manav Jain MD,&nbsp;Priscila A Yamamoto PhD,&nbsp;Amira Soliman PhD,&nbsp;Richard Lowenthal MSc,&nbsp;Valvanera Vozmediano PhD,&nbsp;Stephan Schmidt PhD, FCP,&nbsp;Natalia de Moraes PhD","doi":"10.1002/jcph.70294","DOIUrl":"10.1002/jcph.70294","url":null,"abstract":"<p>Anaphylaxis is a rapid, potentially fatal allergic reaction with a global prevalence of 0.04%-1.8%. Early intramuscular epinephrine administration is recommended. However, fear, pain, cost, or social barriers often delay treatment, leading to poor outcomes. To address these challenges, an intranasal (IN) epinephrine formulation was developed. Pharmacokinetic (PK) data for IN epinephrine are absent in children &lt;4 years (7.5-15 kg) and limited in children ≥4 years. To inform pediatric dosing, we developed a population PK model to support weight-based dosing (≥30 kg, 15-&lt;30 kg, and 7.5-&lt;15 kg) in children. Pooled single-dose IN epinephrine data from six studies (five adults, one pediatric), with 255 subjects and 3564 observations, were analyzed using nonlinear mixed-effects modeling (NONMEM v7.5). Data handling included baseline imputation, exclusion of endogenous concentrations (&gt;4 h), and BLQ management via the M4 method. One- and two-compartment models with allometric scaling by body weight were evaluated. Model performance was assessed using diagnostic plots, objective function value, and prediction-corrected visual predictive checks (pcVPC). Pediatric exposure simulations used CDC-based virtual populations to guide weight-based dosing. A two-compartment model with first-order absorption best described the data, with acceptable relative standard error &lt;30% and no evidence of model misspecification. pcVPC demonstrated good agreement across adult and pediatric subgroups. Simulations indicated that the pediatric doses of 2 mg (≥30 kg) and 1 mg (15-&lt;30 kg) achieved exposure comparable to the adult 2 mg reference, supporting the dosing strategy. Model-informed simulations support weight-based IN epinephrine dosing in young children, addressing a critical gap in anaphylaxis management.</p>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148913495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Portability of Surrogate Endpoints 代理端点的可移植性。
The Journal of Clinical Pharmacology Pub Date : 2026-09-04 DOI: 10.1002/jcph.70286
Henry Bair MD
{"title":"The Portability of Surrogate Endpoints","authors":"Henry Bair MD","doi":"10.1002/jcph.70286","DOIUrl":"10.1002/jcph.70286","url":null,"abstract":"&lt;p&gt;In February 2008, the US Food and Drug Administration (FDA) granted accelerated approval to bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer. In the E2100 trial, median progression-free survival was 11.8 months with bevacizumab plus paclitaxel and 5.9 months with paclitaxel alone; overall survival did not differ significantly.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Progression-free survival was accepted as reasonably likely to predict clinical benefit. The postapproval AVADO and RIBBON-1 trials showed smaller progression-free-survival gains with other chemotherapy backbones and no statistically significant overall survival benefit.&lt;span&gt;&lt;sup&gt;2, 3&lt;/sup&gt;&lt;/span&gt; In November 2011, the FDA withdrew the breast cancer indication, concluding that the demonstrated benefit did not justify the risks in this population.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; Bevacizumab had, by contrast, improved overall survival in metastatic colorectal cancer.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; The comparison does not by itself validate progression-free survival in colorectal cancer; it illustrates that the clinical meaning of tumor control can differ across diseases.&lt;/p&gt;&lt;p&gt;A surrogate endpoint substitutes an observable measure, such as an interval of tumor control or a laboratory value, used in place of a clinical outcome that matters to patients. Its use rests on the inference that an intervention's effect on the surrogate predicts its effect on the clinical outcome. The bevacizumab case shows that the inference from a progression-free-survival effect to a favorable patient-relevant benefit–risk profile depends on disease and treatment context.&lt;/p&gt;&lt;p&gt;Recent systematic reviews in nononcologic chronic disease and oncology raise concerns about the strength and consistency of this inference.&lt;span&gt;&lt;sup&gt;6, 7&lt;/sup&gt;&lt;/span&gt; Most surrogate markers used to support FDA approvals across nononcologic chronic diseases lack high-strength evidence of association with clinical outcomes in the published meta-analysis literature,&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; while treatment-level relationships between progression-free survival and overall survival vary across immune checkpoint inhibitor settings.&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; Better validation is necessary, but validation alone cannot establish whether evidence from one context carries into another.&lt;/p&gt;&lt;p&gt;Surrogate endpoints are best understood as inferential bridges. A bridge of this kind holds within specified conditions and does not automatically hold outside them. Here, context means the conditions under which a particular treatment effect on a surrogate is taken to predict a specified clinical benefit: the disease and disease stage; patient population, including age; intervention mechanism or class; comparator, background therapy, and subsequent treatment; the surrogate definition and timing; and the clinical outcome being predicted. A context change is material when a difference could plausibly alter the surrogate–clinical outcome relationship or introduce","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13543047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148892677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Volumetric Microsampling for Patient-Centric Therapeutic Drug Monitoring in Clinical Pharmacology: A Scoping Review 体积微采样用于临床药理学中以患者为中心的治疗药物监测:范围综述。
The Journal of Clinical Pharmacology Pub Date : 2026-09-04 DOI: 10.1002/jcph.70290
Hari Prabhath Tummala PharmD, MSc, Abbie D. Leino PharmD, PhD, Nathaniel J. Rhodes PharmD, MSc, Kevin J. Downes MD, Marc H. Scheetz PharmD, MSc, Manjunath P. Pai PharmD, FCP
{"title":"Volumetric Microsampling for Patient-Centric Therapeutic Drug Monitoring in Clinical Pharmacology: A Scoping Review","authors":"Hari Prabhath Tummala PharmD, MSc,&nbsp;Abbie D. Leino PharmD, PhD,&nbsp;Nathaniel J. Rhodes PharmD, MSc,&nbsp;Kevin J. Downes MD,&nbsp;Marc H. Scheetz PharmD, MSc,&nbsp;Manjunath P. Pai PharmD, FCP","doi":"10.1002/jcph.70290","DOIUrl":"10.1002/jcph.70290","url":null,"abstract":"<p>Accurate drug concentration measurement is essential for precision pharmacotherapy, but conventional therapeutic drug monitoring (TDM) requires venous sampling, increasing patient burden, and potentially limiting participation in TDM and model-informed precision dosing (MIPD). Volumetric microsampling enables self-collection of small, fixed volume capillary samples for centralized analysis and may reduce hematocrit-related volumetric bias associated with conventional dried blood spots. This scoping review, conducted according to the PRISMA Extension for Scoping Reviews, synthesized 67 patient-cohort studies published from 2014 through 2026. Studies spanned at least 18 countries and multiple clinical specialties. Liquid chromatography-tandem mass spectrometry was used in 61 studies (91%), and most reported validation using or referencing EMA, FDA, IATDMCT, or CLSI criteria. Recovery was minimally affected across evaluated hematocrit ranges for most analytes, and many analytes remained stable in dried samples, although stability varied by analyte and storage conditions. Where assessed, patient preference was high (80%-100%). However, interpretation against established plasma therapeutic ranges often required whole-blood-to-plasma or capillary-to-venous conversion, with inconsistent derivation and validation methods. Fixed conversion factors performed well for lacosamide and levetiracetam but were less reliable for lamotrigine at high concentrations. Several analyte-matrix combinations, including cefepime, vancomycin, meropenem, paclitaxel, abiraterone, and mitotane, did not consistently meet agreement criteria. Volumetric microsampling can support patient-centered drug monitoring when validated for the specific analyte, matrix, device, and clinical application. Future research should prioritize drug-specific optimization, multicenter validation, standardized conversion reporting, and integration with MIPD platforms.</p>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13543046/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148892682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书